Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRONITIN MIST vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BRONITIN MIST contains isoproterenol, a non-selective beta-adrenergic agonist that stimulates beta-1 and beta-2 receptors, leading to bronchodilation via relaxation of bronchial smooth muscle, increased heart rate, and increased contractility.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of bronchial asthma and reversible bronchospasm associated with chronic bronchitis and emphysema
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
For acute bronchospasm: 1-2 inhalations (0.1 mg per inhalation) via aerosol inhaler every 4-6 hours as needed.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life is 3-4 hours in adults; may be prolonged in hepatic or renal impairment, requiring dose adjustment.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) in the liver and other tissues; also undergoes sulfation.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Primarily renal (approximately 70-80% as unchanged drug and metabolites); biliary/fecal excretion accounts for 20-30%.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Approximately 40-60% bound to plasma albumin.
55–65% bound to plasma proteins, primarily albumin.
1.5-2.5 L/kg, indicating extensive distribution into tissues beyond plasma volume.
0.4–0.6 L/kg, indicating distribution into total body water.
Inhalation: 10-20% (depends on device and technique); Oral: 40-60% due to first-pass metabolism.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No dose adjustment required for renal impairment; drug is primarily hepatically metabolized.
No dose adjustment required for renal impairment.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 50%. Class C: avoid use or use with extreme caution.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Children 2-12 years: 1 inhalation (0.05 mg per inhalation) via aerosol inhaler every 4-6 hours; maximum 4 inhalations per day.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Use with caution due to increased sensitivity; start at lower end of dosing range, monitor for tachycardia and hypertension.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
None
No FDA black box warning exists for this drug.
May cause paradoxical bronchospasm,Risk of myocardial ischemia and cardiac arrhythmias,Use with caution in patients with hyperthyroidism, diabetes, and hypertension,May produce significant tachycardia and palpitations
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to isoproterenol or any component,Tachyarrhythmias,Digitalis intoxication (may aggravate arrhythmias)
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid caffeine (coffee, tea, cola, chocolate) as it may increase stimulant effects (tremor, palpitations). No specific food restrictions; however, maintain adequate hydration. Grapefruit juice may affect metabolism of some components (if includes corticosteroid); consult label.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Pregnancy category C. First trimester: No adequate studies; potential risk based on animal studies showing fetal anomalies. Second/third trimester: Possible fetal tachycardia; avoid near term due to risk of uterine relaxation and delayed labor.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Excreted in breast milk; M/P ratio not established. Use caution; potential for adverse effects in infant (e.g., tachycardia). Consider benefits vs risks.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No standardized dose adjustments; pharmacokinetic changes (e.g., increased clearance) may occur, but specific adjustments are not established. Use lowest effective dose under medical supervision.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
BRONITIN MIST delivers a fixed-dose combination of bronchodilators (beta-2 agonist and anticholinergic) via aerosol. Instruct patients to shake the canister well before each use and to prime it with 2 test sprays if not used for >24 hours. Monitor for paradoxical bronchospasm, oropharyngeal irritation, and cardiovascular effects (tachycardia, palpitations). Advise patients to rinse mouth after use to reduce oral candidiasis risk (if contains corticosteroid). Not for acute severe asthma attacks; short-acting rescue inhaler should be available.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Shake the inhaler vigorously before each use.,Prime the inhaler with 2 test sprays into the air if new or not used for more than 24 hours.,Exhale fully, then place mouthpiece in mouth and seal lips around it. Inhale slowly and deeply while pressing the canister down once.,Hold breath for 10 seconds after inhalation, then exhale slowly.,Wait at least 30 seconds between puffs (if more than one is prescribed).,Rinse mouth with water (do not swallow) after each use to prevent thrush and hoarseness.,Do not exceed prescribed dose; overuse may cause increased side effects or worsening symptoms.,Seek emergency medical help if breathing does not improve or worsens after use.,Keep inhaler at room temperature; do not puncture or burn canister even when empty.,Inform your doctor if you have heart disease, high blood pressure, seizures, thyroid problems, or diabetes.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRONITIN MIST vs AEROLATE SR, answered by our medical review team.
BRONITIN MIST is a Bronchodilator that works by BRONITIN MIST contains isoproterenol, a non-selective beta-adrenergic agonist that stimulates beta-1 and beta-2 receptors, leading to bronchodilation via relaxation of bronchial smooth muscle, increased heart rate, and increased contractility.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRONITIN MIST and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRONITIN MIST is: For acute bronchospasm: 1-2 inhalations (0.1 mg per inhalation) via aerosol inhaler every 4-6 hours as needed.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRONITIN MIST and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRONITIN MIST is classified as Category C. Pregnancy category C. First trimester: No adequate studies; potential risk based on animal studies showing fetal anomalies. Second/third trimester: Possible fetal tachycardia; avoi. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.